Targeting epigenetics as atherosclerosis treatment: an updated view

This review discusses the current developments on epigenetic inhibition as treatment for atherosclerosis. RECENT FINDINGS: The first phase III clinical trial targeting epigenetics in cardiovascular disease (CVD), BETonMACE, using the bromodomain inhibitor apabetalone (RVX-208) showed no significant...

Full description

Saved in:
Bibliographic Details
Published in:Curr Opin Lipidol
Main Authors: Neele, Annette E., Willemsen, Lisa, Chen, Hung-Jen, Dzobo, Kim E., de Winther, Menno P.J.
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2020
Subjects:
THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7752220/
https://ncbi.nlm.nih.gov/pubmed/33027226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOL.0000000000000711
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items